search
Back to results

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes (MIPOD)

Primary Purpose

Non Insulin Dependent Diabetes, Pregnancy

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Metformin
Insulin
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Insulin Dependent Diabetes focused on measuring Non Insulin Dependent Diabetes, Pregnancy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Receiving prenatal care at University of North Carolina (UNC), Chapel Hill Obstetric clinics and planning delivery at UNC Women's Hospital
  • Diagnosis of Diabetes prior to pregnancy with use of an oral hypoglycemic agent or dietary control
  • Diagnosis of early gestational diabetes prior to 20 weeks gestation via abnormal 3 hour glucose challenge testing using the national diabetes data group (NDDG)criteria
  • Less than 24 weeks at study enrollment
  • Singleton or twin pregnancy
  • English or Spanish speaking
  • Able to give informed consent

Exclusion Criteria:

  • End organ complications of diabetes (retinopathy, renal insufficiency, etc.)
  • Prior need for insulin for glycemic control
  • History of diabetic ketoacidosis (DKA) or hyperosmolar state
  • Prior adverse reaction (ie. lactic acidosis) or allergy to Metformin
  • Kidney or liver disease
  • Significant medical co-morbidities (lupus, cystic fibrosis, etc.) Hypertension controlled on one medication, well controlled asthma, and well controlled thyroid disease are not excluded.

Sites / Locations

  • University of North Carolina Hospitals Obstetric Clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Metformin

Insulin

Arm Description

Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.

Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.

Outcomes

Primary Outcome Measures

Blood Glucose Measurements
Patients self monitored glucose measures throughout pregnancy to aid glycemic control. Fasting morning measures and postprandial measures were taken at 1 hour after breakfast, lunch, and dinner.

Secondary Outcome Measures

Number of Patients With Obstetric Complications
Maternal complications were stillbirths, major malformations, shoulder dystocia, or postpartum hemorrhage requiring transfusion.
Maternal Weight Gain
Number of Babies With Neonatal Hypoglycemia
Initial neonatal glucose < 40 mg/dL
Glycosylated Hemoglobin (HbA1c) by Pregnancy Trimester
Percent of Glucose Values at or Below Fasting Goal (<95 mg/dL)
NUMBER OF ASSESSMENTS OF FASTING GLUCOSE VALUES <95
Percent of Glucose Values at or Below Postprandial Goal (<130 mg/dL)
NUMBER OF ASSESSMENTS OF POSTPRANDIAL GLUCOSE VALUES <130
Number of Episodes Maternal Hypoglycemia
Maternal glucose < 60 mg/dL
Number of Babies With Adverse Neonatal Outcomes
Resuscitation in the delivery room, preterm birth < 37 weeks, neonatal intensive care unit care, birth injury or diagnosis of neonatal complication, glucose infusion, antibiotics, or phototherapy.

Full Information

First Posted
February 2, 2009
Last Updated
April 21, 2017
Sponsor
University of North Carolina, Chapel Hill
Collaborators
WakeMed Health and Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT00835861
Brief Title
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
Acronym
MIPOD
Official Title
Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
August 2008 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
April 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
WakeMed Health and Hospitals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin. Metformin is widely used in the non-pregnant population for glycemic control, and has been used in pregnancy for other indications without adverse maternal or fetal outcomes. What remains unproven is the ability of Metformin to adequately control glucose in women during pregnancy. Our goal is to randomize 100 women who enter pregnancy with diabetes that is controlled by either diet or an oral agent and women who are found to have an abnormal glucose challenge test at less than 20 weeks to either standard treatment with weight based Regular and neutral protamine Hagedorn (NPH) insulin or Metformin. Our hypothesis is that Metformin will provide glycemic control that is equivalent to insulin in these women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Insulin Dependent Diabetes, Pregnancy
Keywords
Non Insulin Dependent Diabetes, Pregnancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Metformin
Arm Type
Experimental
Arm Description
Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
Arm Title
Insulin
Arm Type
Active Comparator
Arm Description
Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Glucophage
Intervention Description
Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
Intervention Type
Drug
Intervention Name(s)
Insulin
Other Intervention Name(s)
Regular Insulin, Novolin R, Humulin R, NPH Insulin, Novolin N, Humulin N
Intervention Description
Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
Primary Outcome Measure Information:
Title
Blood Glucose Measurements
Description
Patients self monitored glucose measures throughout pregnancy to aid glycemic control. Fasting morning measures and postprandial measures were taken at 1 hour after breakfast, lunch, and dinner.
Time Frame
Daily fasting and 1-hr post prandial measures were taken from time of enrollment until delivery
Secondary Outcome Measure Information:
Title
Number of Patients With Obstetric Complications
Description
Maternal complications were stillbirths, major malformations, shoulder dystocia, or postpartum hemorrhage requiring transfusion.
Time Frame
Throughout pregnancy until hospital discharge following delivery.
Title
Maternal Weight Gain
Time Frame
Baseline throughout pregnancy until last prenatal visit.
Title
Number of Babies With Neonatal Hypoglycemia
Description
Initial neonatal glucose < 40 mg/dL
Time Frame
Time of delivery through hospital discharge
Title
Glycosylated Hemoglobin (HbA1c) by Pregnancy Trimester
Time Frame
1st, 2nd, and 3rd trimester
Title
Percent of Glucose Values at or Below Fasting Goal (<95 mg/dL)
Description
NUMBER OF ASSESSMENTS OF FASTING GLUCOSE VALUES <95
Time Frame
Baseline throughout pregnancy until time of delivery
Title
Percent of Glucose Values at or Below Postprandial Goal (<130 mg/dL)
Description
NUMBER OF ASSESSMENTS OF POSTPRANDIAL GLUCOSE VALUES <130
Time Frame
Baseline throughout pregnancy until time of delivery
Title
Number of Episodes Maternal Hypoglycemia
Description
Maternal glucose < 60 mg/dL
Time Frame
Baseline throughout pregnancy until time of delivery
Title
Number of Babies With Adverse Neonatal Outcomes
Description
Resuscitation in the delivery room, preterm birth < 37 weeks, neonatal intensive care unit care, birth injury or diagnosis of neonatal complication, glucose infusion, antibiotics, or phototherapy.
Time Frame
Delivery until hospital discharge

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Receiving prenatal care at University of North Carolina (UNC), Chapel Hill Obstetric clinics and planning delivery at UNC Women's Hospital Diagnosis of Diabetes prior to pregnancy with use of an oral hypoglycemic agent or dietary control Diagnosis of early gestational diabetes prior to 20 weeks gestation via abnormal 3 hour glucose challenge testing using the national diabetes data group (NDDG)criteria Less than 24 weeks at study enrollment Singleton or twin pregnancy English or Spanish speaking Able to give informed consent Exclusion Criteria: End organ complications of diabetes (retinopathy, renal insufficiency, etc.) Prior need for insulin for glycemic control History of diabetic ketoacidosis (DKA) or hyperosmolar state Prior adverse reaction (ie. lactic acidosis) or allergy to Metformin Kidney or liver disease Significant medical co-morbidities (lupus, cystic fibrosis, etc.) Hypertension controlled on one medication, well controlled asthma, and well controlled thyroid disease are not excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashley Hickman, MD
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina Hospitals Obstetric Clinics
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23096052
Citation
Hickman MA, McBride R, Boggess KA, Strauss R. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol. 2013 Jun;30(6):483-90. doi: 10.1055/s-0032-1326994. Epub 2012 Oct 24.
Results Reference
derived

Learn more about this trial

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

We'll reach out to this number within 24 hrs